Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-01-25FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approves a supplemental application for ustekinumab (Stelara) from Janssen Biotech, Inc.
-
CLINICAL_TRIALS trial_result · 2013-01-21Clinical Trial Update: Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]
A Phase 3 trial comparing ABT-874 with etanercept and placebo in adults with moderate to severe chronic plaque psoriasis has completed.
-
CLINICAL_TRIALS trial_result · 2013-01-18Clinical Trial Update: Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]
This Phase 3 trial compared ABT-874 to Etanercept and placebo in adults with moderate to severe chronic plaque psoriasis; the study status i…
-
CLINICAL_TRIALS trial_result · 2012-12-11Clinical Trial Update: Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis [Phase 2]
This update reports the completion of a Phase 2 pivotal efficacy and safety trial of FP187 for moderate to severe plaque psoriasis.
-
FDA approval · 2012-12-10FDA Approved: ENBREL — Supplemental Application (Immunex Corporation)
The FDA approved a supplemental application for ENBREL (etanercept) submitted by Immunex Corporation.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-12-05Clinical Trial Update: Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis [Phase 4]
Phase 4 trial update for Taclonex ointment with hydrogel patch occlusion in psoriasis; study terminated with results posted in 2012.
-
FDA approval · 2012-12-04FDA Approved: ENBREL — Supplemental Application (Immunex Corporation)
FDA approved a supplemental application for Enbrel (etanercept) submitted by Immunex Corporation.
-
FDA label_change · 2012-11-30FDA Approved: TACLONEX — Supplemental Application (LEO Pharma Inc.)
The FDA approved a supplemental application for Taclonex (calcipotriene and betamethone dipropionate) submitted by LEO Pharma Inc., resultin…
-
CLINICAL_TRIALS trial_result · 2012-11-22Clinical Trial Update: A Phase IV Clinical Trial to Study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis [Phase 4]
Phase IV trial assessing safety, tolerability and efficacy of Tinefcon in plaque psoriasis has completed.
-
CLINICAL_TRIALS trial_result · 2012-11-21Clinical Trial Update: An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis [Phase 3]
A Phase 3 trial compares CNTO 1275 (ustekinumab) to etanercept to evaluate efficacy and safety in adults with plaque psoriasis.
-
FDA label_change · 2012-10-17FDA Approved: TACLONEX — Supplemental Application (LEO Pharma Inc.)
FDA approved a supplemental application for Taclonex (calcipotriene and betamethasone dipropionate) from LEO Pharma, resulting in a label up…
-
FDA approval · 2012-09-28FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)
The FDA approved a supplemental application for HUMIRA (adalimumab) submitted by Cordavis Limited.
-
FDA approval · 2012-09-27FDA Approved: CALCIPOTRIENE — Supplemental Application (Mayne Pharma)
The FDA approved a supplemental application for CALCIPOTRIENE submitted by Mayne Pharma.
-
FDA label_change · 2012-09-07FDA Approved: CLOBEX — Supplemental Application (Galderma Laboratories, L.P.)
FDA approved a supplemental application for CLOBEX (clobetasol propionate) from Galderma Laboratories, L.P. The approval updates the product…
-
CLINICAL_TRIALS trial_result · 2012-08-24Clinical Trial Update: A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis [Phase 3]
Phase 3 study assessing safety and effectiveness of ustekinumab for moderate to severe plaque-type psoriasis has completed with results post…
-
CLINICAL_TRIALS research · 2012-08-03Clinical Trial Update: A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF [Phase 1]
Phase 1 study investigating downregulation of epidermal growth factor receptors in the skin after topical exposure to epidermal growth facto…
-
CLINICAL_TRIALS trial_result · 2012-07-26Clinical Trial Update: Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315) [Phase 3]
Phase 3 study evaluating dose optimization of infliximab in adults with moderate-to-severe plaque psoriasis was terminated; results were pos…
-
CLINICAL_TRIALS trial_result · 2012-07-18Clinical Trial Update: A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis [Phase 4]
A Phase 4 clinical trial update evaluating Stelara (ustekinumab) for scalp psoriasis and plaque psoriasis.
-
FDA approval · 2012-05-24FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)
FDA approved a supplemental application for HUMIRA (adalimumab) submitted by Cordavis Limited.
-
FDA approval · 2012-05-11FDA Approved: TAZAROTENE — Original Application (Mayne Pharma Inc.)
The FDA approved Mayne Pharma's original application for tazarotene, a topical retinoid, for dermatologic use.
-
CLINICAL_TRIALS withdrawal · 2012-05-07Clinical Trial Update: To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis [Phase 3]
A Phase 3 trial evaluating NYC 0462 ointment for plaque psoriasis has been withdrawn. Sponsor Fougera Pharmaceuticals Inc.
-
FDA approval · 2012-05-02FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ustekinumab (Stelara) from Janssen Biotech, Inc., resulting in a labeling change/addition.
-
CLINICAL_TRIALS trial_result · 2012-04-23Clinical Trial Update: Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis [Phase 4]
Phase 4 study evaluating etanercept for moderate-to-severe psoriasis has completed, with results posted in 2012.
-
CLINICAL_TRIALS trial_result · 2012-04-03Clinical Trial Update: Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva) [Phase 4]
Phase 4 trial evaluating topical calcipotriene/betamethasone (Taclonex) for localized breakthrough psoriasis in patients receiving efalizuma…
-
CLINICAL_TRIALS trial_result · 2012-03-21Clinical Trial Update: Study Evaluating Enbrel (Etanercept) in Adult Patients With Plaque Psoriasis
Pfizer-sponsored study evaluating Enbrel (etanercept) in adult patients with plaque psoriasis has completed. The document notes the trial st…